ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2018
Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Inflammasome Dynamics in the High-Risk Clone ST235 with Altered Pyoverdine Structures.International journal of molecular sciences · 2026Article
- Individual contributions of exotoxins S and T on internalizedInfection and immunity · 2026Article
- Comparison of clinical and microbiological features between mucoid and non-mucoidMicrobiology spectrum · 2026Article
- Interkingdom signaling elicited by bacterial extracellular vesicles in human cystic fibrosis airway epithelium and neutrophils.Frontiers in cellular and infection microbiology · 2026Article
- A chronicInfection and immunity · 2025Article
- State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Review
- Article
- OvercomingAntibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.npj antimicrobials and resistance · 2024Article
- DYNAMIC RISK PREDICTION TRIGGERED BY INTERMEDIATE EVENTS USING SURVIVAL TREE ENSEMBLES.The annals of applied statistics · 2023Article
- Infection is associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2022Article
- Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Alkyl-Quinolones derivatives as potential biomarkers for Pseudomonas aeruginosa infection chronicity in Cystic Fibrosis.Scientific reports · 2021Article
- Adaptation and genomic erosion in fragmented Pseudomonas aeruginosa populations in the sinuses of people with cystic fibrosis.Cell reports · 2021Article
- Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections.Microorganisms · 2021Review
- Impairment in inflammasome signaling by the chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients results in an increase in inflammatory response.Cell death & disease · 2021Article
- Serum-Associated Antibiotic Tolerance in Pediatric Clinical Isolates of Pseudomonas aeruginosa.Journal of the Pediatric Infectious Diseases Society · 2020Article
- GENERALIZED ACCELERATED RECURRENCE TIME MODEL IN THE PRESENCE OF A DEPENDENT TERMINAL EVENT.The annals of applied statistics · 2020Article
- Virulence attenuating combination therapy: a potential multi-target synergy approach to treatRSC medicinal chemistry · 2020Review
- Evaluation of Inhaled Tobramycin in Early Eradication ofThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundWhile the emergence of chronic and mucoid Pseudomonas aeruginosa (Pa) infection are both associated with poorer outcomes among CF patients, their relationship is poorly understood. We examined the longitudinal relationship of incident, chronic and mucoid Pa in a contemporary, young CF cohort in the current era of Pa eradication therapy.
methodsThis retrospective cohort was comprised of patients in the U.S. CF Foundation Patient Registry born 2006-2015, diagnosed before age 2, and with at least 3 respiratory cultures annually. Incidence and age-specific prevalence of Pa infection stages (initial and chronic [≥ 3Pa+cultures in prior year]) and of mucoid Pa were summarized. Transition times and the interaction between Pa stage and acquisition of mucoid Pa were examined via Cox models.
resultsAmong the 5592 CF patients in the cohort followed to a mean age of 5.5years, 64% (n=3580) acquired Pa. Of those, 13% (n=455) developed chronic Pa and 17% (n=594) cultured mucoid Pa. Among those with mucoid Pa, 36% (211/594) had it on their first recorded Pa+culture, while mucoid Pa emerged at or after entering the chronic stage in 12% (73/594). Mucoidy was associated with significantly increased risk of transition to chronic Pa infection (HR=2.59, 95% CI 2.11, 3.19).
conclusionsTwo-thirds of early-diagnosed young children with CF acquired Pa during a median 5.6years of follow up, among whom 13% developed chronic Pa and 17% acquired mucoid Pa. Contrary to our hypothesis, 87% of young children who developed mucoid Pa did so before becoming chronically infected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.